Which Tyrosine Kinase Inhibitor Must We Apply Before? A Case Report of Crizotinib-resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutations

Basit Öğe Kaydı
dc.authoridSivrikoz, Oya nermin/0000-0001-7454-2812
dc.authorscopusid23003802600
dc.authorscopusid35576663600
dc.authorscopusid6701376935
dc.authorscopusid15843556800
dc.authorscopusid24475644100
dc.authorscopusid57249750400
dc.authorscopusid23096457100
dc.authorwosidSivrikoz, Oya nermin/V-9335-2017
dc.contributor.authorCokmert, S.
dc.contributor.authorVeral, A.
dc.contributor.authorAkyurek, N.
dc.contributor.authorKececi, S. D.
dc.contributor.authorSivrikoz, O.
dc.contributor.authorYilmaz, E.
dc.contributor.authorTanriverdi, O.
dc.date.accessioned2023-01-12T20:19:14Z
dc.date.available2023-01-12T20:19:14Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractThe concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are very rare scenarios. Until now, 42 cases described in the literature have all been treated by different drugs. There is no overall consensus regarding the treatment for this adenocarcinoma subgroup. We report here a case of lung adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rear-rangement in primary tumour, EGFR mutation in exon 21 (L858R) and no ALK rearrangement in its synchronous metastasis. We treated this patient with crizotinib as the second-line therapy (after the first line docetaxel-cisplatin chemotherapy), but no response was obtained. The therapeutic choice for the lung adenocancer patients with concomitant EGFR mutation and ALK rearrangement is unclear. Examination of c-ros oncogene 1 mutation can be used as an indicator in the prediction of the crizotinib treatment success. The ALK mutation may not responsible for the resistance to EGFR-tyrosine kinase inhibitors (TKI), and EGFR-TKI can be initiated to EGFR and ALK dual mutant patients as the first treatment.en_US
dc.identifier.doi10.7727/wimj.2016.096
dc.identifier.endpage153en_US
dc.identifier.issn0043-3144
dc.identifier.issn2309-5830
dc.identifier.issn0043-3144en_US
dc.identifier.issn2309-5830en_US
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85114392546en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage148en_US
dc.identifier.urihttps://doi.org/10.7727/wimj.2016.096
dc.identifier.urihttps://hdl.handle.net/11454/79066
dc.identifier.volume69en_US
dc.identifier.wosWOS:000696572200004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherUniv West Indies Faculty Medical Sciencesen_US
dc.relation.ispartofWest Indian Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdenocanceren_US
dc.subjectanaplastic lymphoma kinaseen_US
dc.subjectcrizotiniben_US
dc.subjectlung epidermal growth factor receptor mutationen_US
dc.subjectCell Lung-Canceren_US
dc.subjectFactor Receptor Mutationen_US
dc.subjectAlk Rearrangementen_US
dc.subjectFusion Geneen_US
dc.subjectAdenocarcinomaen_US
dc.subjectGefitiniben_US
dc.subjectResponsivenessen_US
dc.subjectTranslocationen_US
dc.titleWhich Tyrosine Kinase Inhibitor Must We Apply Before? A Case Report of Crizotinib-resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutationsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu